-
438P Adjuvant nivolumab after neoadjuvant chemoradiotherapy and surgery for patients with esophageal or gastroesophageal junction cancer: A nationwide real-world matched comparison of overall survival
Rob H.A. Verhoeven, Steven C. Kuijper, Marije Slingerland, Bas P. L. Wijnhoven, Mark I. van Berge Henegouwen, Peter S.N. van Rossum, +4 more
1citations -
1683TiP OMIT trial: omitting therapeutic lymph node dissection in patients with stage IIIB/C melanoma and major pathological response in the index lymph node after neoadjuvant immunotherapy
Antonius W Schurink, Evalyn E.A.P. Mulder, Lukas B. Been, James van Bastelaar, Han J. Bonenkamp, Anneriet E. Dassen, +10 more
1citations -
1550P Addressing uncertainties of clinical value and improving access for newly authorised indications through DRUG-Access Protocol (DAP)-like platforms: Joint collection and evaluation of real-world evidence2024 Annals of Oncology article Economics, Econometrics and Finance Pharmaceutical Economics and Policy Open access
Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, A. Huisman, Hans J.L. Timmer, L. Fagereng, Åslaug Helland, Bettina Ryll, +9 more
1citations -
O-4 Average cumulative relative dose of adjuvant chemotherapy is more important than average relative dose intensity for colorectal cancer survival, with implications for treating obese patients: The OCTOPUS consortium
Corinna Slawinski, Lee Malcomson, Jorge Barriuso, Hongwei Guo, Andrea Harkin, Timothy J. Iveson, +3 more
1citations -
649TiP PRIMORDIUM: A randomized, international, trial-in-progress of adding apalutamide to radiotherapy and an LHRH agonist in high-risk patients with PSMA-PET-positive hormone-sensitive prostate cancer2021 Annals of Oncology article Medicine Prostate Cancer Diagnosis and Treatment Open access cited by 1 patent
Boris Alexander Hadaschik, Stefano Fanti, Piet Ost, Nina Tunariu, Cosimo DE NUNZIO, Luca Antoni, +3 more
1citations -
707P Personalised dosing of oral targeted therapies in oncology: The era of therapeutic drug monitoring2023 Annals of Oncology article Pharmacology, Toxicology and Pharmaceutics Pharmacogenetics and Drug Metabolism Open access
Maud B. A. van der Kleij, Niels A.D. Guchelaar, Marinda Meertens, Eline L. Giraud, Roos F. Bleckman, Alexander L.T. Imholz, +14 more
1citations -
1535O Cost and value of EMA-registered checkpoint inhibitors for solid tumours in the Netherlands2024 Annals of Oncology article Economics, Econometrics and Finance Health Systems, Economic Evaluations, Quality of Life Open access
Atse H Huisman, Simone N. Koole, Machteld Wymenga, A. Pisters, Hans A. J. Gelderblom, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani
1citations -
1542MO Mapping the scale of off-label use in oncology: An important step in harmonising access2024 Annals of Oncology article Economics, Econometrics and Finance Pharmaceutical Economics and Policy Open access
Hans J.L. Timmer, Atse H Huisman, L. Fagereng, Hans A. J. Gelderblom, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani
1citations -
115P Gene rearrangements, actionability and access to precision medicine: Results from the ARCAGEN study2024 Annals of Oncology article Biochemistry, Genetics and Molecular Biology Cancer Genomics and Diagnostics Open access
Marie Morfouace, Julliete Cristina de Oliveira, Marc Pracht, Nicolas Penel, Sabine Tejpar, M-S. Robert, +10 more
1citations -
596P Dose-individualisation of fluoropyrimidines in DPYD wild-type patients: Final results from the Alpe2U study2024 Annals of Oncology article Pharmacology, Toxicology and Pharmaceutics Pharmacogenetics and Drug Metabolism Open access
Niels Heersche, Jonathan Emanuel Knikman, M. De With, Marta López‐Yurda, Arnold Baars, G. J. M. Creemers, +13 more
1citations -
421TiP OPTImaL: Optimisation of treatment for patients with low stage triple-negative breast cancer with high stromal tumor-infiltrating lymphocytes2025 Annals of Oncology article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
A.L. Rolfes, Gil Awada, Sara Balduzzi, Antonios Daletzakis, I. Mandjes, Timo Völker, +9 more
1citations -
2694P Long-term efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): 2-year results from the MOTION phase III trial2025 Annals of Oncology article Medicine Musculoskeletal synovial abnormalities and treatments Open access
Sebastian Bauer, Vivek A. Bhadri, Hans A. J. Gelderblom, S. Stacchiotti, Andrew J. Wagner, Meike van de Sande, +12 more
1citations